Oral Squamous Cell Carcinoma (OSCC)NCT07778615
Immunohistochemical Expression of Cyclin D1 in Oral Squamous Cell Carcinoma: Relationship With Clinicodemographic and Histopathological Features
An observational study of Oral Squamous Cell Carcinoma (OSCC), run by Sohag University at 1 site in Egypt.
Trial summary
Oral squamous cell carcinoma is a major public health problem , especially in West Asian countries. Cyclin D1 accelerates cell cycle and thus may be implicated in uncontrolled cellular proliferation and tumor progression. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Oral Squamous Cell Carcinoma (OSCC)
- What is being tested?
- immunohistochemical expression of Cyclin D1 on oral squamous cell carcinoma tissue sections
- Type of treatment
- Pill or oral medicine
- How many people
- 34 participants
- Where
- 1 siteEgypt
- Study dates
- Jan 2017to Jun 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: a retrospective, observational study
Who may be able to join
- patients with oral squamous cell carcinoma.
Who cannot join
- patients with oral carcinoma other than squamous cell carcinoma.
- patients who received pre-operative radiotherapy.
- patients with inadequate clinical data.
Trial locations and contacts
1 site in 1 country.
About this study
Oral squamous cell carcinoma is a major public health problem , especially in West Asian countries. Cyclin D1 accelerates cell cycle and thus may be implicated in uncontrolled cellular proliferation and tumor progression.
Read the detailed description
Oral squamous cell carcinoma is a major public health problem in different parts of the world. Despite marvelous improvement in treatment modalities -surgical approaches, chemotherapy and radiotherapy- the overall survival ad disease-free survival remain unchanged. so, there a need for studying tumor biology and micro environment. Cyclin D1 is a protein which enhances cell cycle through binding with cyclin-dependent kinases. Over expression of Cyclin D1 may by responsible for the aggressive behavior of oral squamous cell carcinoma through uncontrolled cellular proliferation. in current study, we have detected Cyclin D1 expression in 34 cases of oral squamous cell carcinoma. We detected relationship between intensity of expression and certain parameters as tumor grade, lymphovascular and perineural invasion.
- Conditions
- Oral Squamous Cell Carcinoma (OSCC)
- Being tested
- immunohistochemical expression of Cyclin D1 on oral squamous cell carcinoma tissue sections
- Keywords
- Oral Squamous Cell Carcinoma, Cyclin D1, Immunohistochemistry, Labelling index
- Medical subject headings
- Squamous Cell Carcinoma of Head and Neck
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
immunohistochemical expression of Cyclin D1 on oral squamous cell carcinoma tissue sectionsBiological
| Study group | Role | What they receive |
|---|---|---|
| cases with oral squamous cell carcinoma | Formalin-fixed, Paraffin-embedded tissue blocks obtained from 34 patients with oral squamous cell carcinoma Receives: Biological: immunohistochemical expression of Cyclin D1 on oral squamous cell carcinoma tissue sections |
What is being measured
The primary outcome is the main question the study is designed to answer.
immunohistochemical expression of Cyclin D1 in Oral Squamous Cell Carcinoma
detection of both intensity staining and tumor cells percentage of Cyckin D1 in studied cases of Oral Squamous Cell Carcinoma, and then relate intensity and percentage of Cyclin D1 with patients' ages, sexes, tumor grade, tumor site , lymphovascular invasion and perineural invasion.
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Aug 2026
- Study startJan 2017
- Primary completionDec 2025
- Study completionJun 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Oral Squamous Cell Carcinoma (OSCC)Studies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 34 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Maisa Hashem Mohammed, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07778615
- Sponsor's protocol ID
- Soh-Med-26-8-12PD
- Status last verified
- Aug 2026
- First submitted
- 18 Aug 2026
- Last updated
- 21 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Tan Y, Wang Z, Xu M, Li B, Huang Z, Qin S, Nice EC, Tang J, Huang C. Oral squamous cell carcinomas: state of the field and emerging directions. Int J Oral Sci. 2023 Sep 22;15(1):44. doi: 10.1038/s41368-023-00249-w.
PubMed 37736748
Study at a glance
From the registry record, last updated by the sponsor on 21 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Immunohistochemical Expression of Cyclin D1 in Oral Squamous Cell Carcinoma: Relationship With Clinicodemographic and Histopathological Features
- ClinicalTrials.gov ID
- NCT07778615
- Acronym / sponsor ID
- Soh-Med-26-8-12PD
- Conditions
- Oral Squamous Cell Carcinoma (OSCC)
- Keywords
- Oral Squamous Cell Carcinoma, Cyclin D1, Immunohistochemistry, Labelling index
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 34 participants (actual)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- Jan 2017 (actual)
- Primary completion
- Dec 2025 (actual)
- Study completion
- Jun 2026 (actual)
- First posted
- 21 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Oral squamous cell carcinoma is a major public health problem , especially in West Asian countries. Cyclin D1 accelerates cell cycle and thus may be implicated in uncontrolled cellular proliferation and tumor progression.
Detailed description
Oral squamous cell carcinoma is a major public health problem in different parts of the world. Despite marvelous improvement in treatment modalities -surgical approaches, chemotherapy and radiotherapy- the overall survival ad disease-free survival remain unchanged. so, there a need for studying tumor biology and micro environment. Cyclin D1 is a protein which enhances cell cycle through binding with cyclin-dependent kinases. Over expression of Cyclin D1 may by responsible for the aggressive behavior of oral squamous cell carcinoma through uncontrolled cellular proliferation. in current study, we have detected Cyclin D1 expression in 34 cases of oral squamous cell carcinoma. We detected relationship between intensity of expression and certain parameters as tumor grade, lymphovascular and perineural invasion.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| cases with oral squamous cell carcinoma | – | Biological: immunohistochemical expression of Cyclin D1 on oral squamous cell carcinoma tissue sectionsFormalin-fixed, Paraffin-embedded tissue blocks obtained from 34 patients with oral squamous cell carcinoma |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- a retrospective, observational study
Key inclusion criteria (1 listed)
- patients with oral squamous cell carcinoma.
Key exclusion criteria (3 listed)
- patients with oral carcinoma other than squamous cell carcinoma.
- patients who received pre-operative radiotherapy.
- patients with inadequate clinical data.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| immunohistochemical expression of Cyclin D1 on oral squamous cell carcinoma tissue sections | Biological | cases with oral squamous cell carcinoma |
Primary outcome
immunohistochemical expression of Cyclin D1 in Oral Squamous Cell Carcinoma
Time frame: 6 months
detection of both intensity staining and tumor cells percentage of Cyckin D1 in studied cases of Oral Squamous Cell Carcinoma, and then relate intensity and percentage of Cyclin D1 with patients' ages, sexes, tumor grade, tumor site , lymphovascular invasion and perineural invasion.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Aug 2026.
- Background: PubMed 37736748Tan Y, Wang Z, Xu M, Li B, Huang Z, Qin S, Nice EC, Tang J, Huang C. Oral squamous cell carcinomas: state of the field and emerging directions. Int J Oral Sci. 2023 Sep 22;15(1):44. doi: 10.1038/s41368-023-00249-w.
- Individual participant dataSharing planned: Undecided
Related trials for Oral Squamous Cell Carcinoma (OSCC)
Recruiting
Effectiveness of Hydrogen Water Intervention on Acute Oral Inflammation, Oral Microbiota, and Pain Following Free Flap Reconstruction in Patients With Oral Cancer
Oral Squamous Cell Carcinoma (OSCC), Postoperative Pain
Active, not recruitingObservational study
Objective Response Rate of Ivonescimab With Chemotherapy in Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma
HNSCC, OSCC
Active, not recruitingObservational study
Comparison of TLC (Total Leucocyte Count), Neutrophils and Monocytes in Oral Squamous Cell Carcinoma and Pre-malignant Disorders
Oral Squamous Cell Carcinoma (OSCC), Premalignant Lesion
RecruitingPhase 2
Iparomlimab and Tuvonralimab With With Cetuximab in Resectable OSCC
Head and Neck Cancer
Not yet recruitingPhase 2
ImmunoADC Therapy for Induction Conversion in Patients With Stage IVB OSCC/OPSCC
Stage IVB Oral Cavity Squamous Cell Carcinoma, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Oral Squamous Cell Carcinoma (OSCC), run by Sohag University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
immunohistochemical expression of Cyclin D1 in Oral Squamous Cell Carcinoma (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07778615, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Aug 2026.